Novavax (LTS:0UP6) Change In Payables And Accrued Expense : $-421 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Novavax Change In Payables And Accrued Expense?

Novavax's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $-272 Mil. It means Novavax's Accounts Payable & Accrued Expense declined by $272 Mil from Dec. 2023 to Mar. 2024 .

Novavax's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-379 Mil. It means Novavax's Accounts Payable & Accrued Expense declined by $379 Mil from Dec. 2022 to Dec. 2023 .

Novavax Change In Payables And Accrued Expense Historical Data

The historical data trend for Novavax's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Change In Payables And Accrued Expense Chart

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-11.49

163.16

600.33

913.40

-378.81

Novavax Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-230.10	-213.14	93.98	-29.54	-272.46

Novavax Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-421 Mil.

Novavax Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Novavax's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax (LTS:0UP6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (LTS:0UP6) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

NVAX:USA NVAX:Mexico NVV1:Germany

Address

21 Firstfield Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Novavax (LTS:0UP6) Headlines

No Headlines